BEAM Stock Overview
A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Beam Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.29 |
| 52 Week High | US$49.50 |
| 52 Week Low | US$20.84 |
| Beta | 1.86 |
| 11 Month Change | 9.24% |
| 3 Month Change | 3.14% |
| 1 Year Change | -14.18% |
| 33 Year Change | -69.12% |
| 5 Year Change | n/a |
| Change since IPO | 34.88% |
Recent News & Updates
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Nov 07Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price
Oct 28
Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
Sep 29Recent updates
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Nov 07Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price
Oct 28Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
Sep 29We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
Sep 04Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jul 12Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Shareholder Returns
| BEAM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.0% | -7.5% | -1.2% |
| 1Y | -14.2% | 14.1% | 30.4% |
Return vs Industry: BEAM underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: BEAM underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| BEAM volatility | |
|---|---|
| BEAM Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BEAM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BEAM's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 472 | John Evans | beamtx.com |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Beam Therapeutics Inc. Fundamentals Summary
| BEAM fundamental statistics | |
|---|---|
| Market cap | US$2.01b |
| Earnings (TTM) | -US$143.59m |
| Revenue (TTM) | US$349.64m |
5.8x
P/S Ratio-14.0x
P/E RatioIs BEAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BEAM income statement (TTM) | |
|---|---|
| Revenue | US$349.64m |
| Cost of Revenue | US$406.19m |
| Gross Profit | -US$56.55m |
| Other Expenses | US$87.04m |
| Earnings | -US$143.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.80 |
| Gross Margin | -16.17% |
| Net Profit Margin | -41.07% |
| Debt/Equity Ratio | 0% |
How did BEAM perform over the long term?
See historical performance and comparison